In accordance with Section 28a of the Danish Securities Trading Act,
Novo Nordisk is required on a daily basis to publish trading in Novo
Nordisk shares by the company's board members, executives and their
associated persons as reported by those persons to Novo Nordisk.
As from 2004, members of Novo Nordisk's Executive Management and the
other members of the Senior Management Board have participated in a
performance-based incentive programme where a proportion of the
calculated shareholder value creation has been allocated to a joint
pool for the participants. For 2004, 252,688 shares were allocated to
the joint pool and the market value of the scheme was expensed in the
accounts for 2004. In accordance with the principles of the incentive
programme, the Board of Directors of Novo Nordisk A/S on 30 January
2008 evaluated that the conditions for release of the joint pool of
shares have been fulfilled. Accordingly, the shares in the joint pool
were transferred to 22 current and former members of senior
management on 31 January 2008.
Please find below a statement of the transfer of shares to the
members of Executive Management in accordance with the above and the
subsequent trading in these shares by the members of Executive
Management.
+-------------------------------------------------------------------+
| Name | Lars Rebien Sørensen |
|--------------------------+----------------------------------------|
| Reason for reporting | Chief Executive Officer |
|--------------------------+----------------------------------------|
| Financial instrument and | Novo Nordisk B shares DK 006010261 |
| ID code | |
|--------------------------+----------------------------------------|
| Type of transaction | Other transaction (transfer of shares |
| | in accordance with long-term incentive |
| | programme) |
|--------------------------+----------------------------------------|
| Date of transaction | 31 January 2008 |
|--------------------------+----------------------------------------|
| Place of transaction | OMX The Nordic Exchange Copenhagen |
|--------------------------+----------------------------------------|
| Volume of transaction | 26,134 shares |
|--------------------------+----------------------------------------|
| Total value of | DKK 0 (transferred in accordance with |
| transaction | the long-term incentive programme for |
| | 2004) |
+-------------------------------------------------------------------+
+-------------------------------------------------------------------+
| Name | Lars Rebien Sørensen |
|---------------------------------+---------------------------------|
| Reason for reporting | Chief Executive Officer |
|---------------------------------+---------------------------------|
| Financial instrument and ID | Novo Nordisk B shares DK |
| code | 006010261 |
|---------------------------------+---------------------------------|
| Type of transaction | Sale of shares |
|---------------------------------+---------------------------------|
| Date of transaction | 31 January 2008 |
|---------------------------------+---------------------------------|
| Place of transaction | OMX The Nordic Exchange |
| | Copenhagen |
|---------------------------------+---------------------------------|
| Volume of transaction | 26,134 shares |
|---------------------------------+---------------------------------|
| Total value of transaction | DKK 8,131,855 |
+-------------------------------------------------------------------+
+-------------------------------------------------------------------+
| Name | Jesper Brandgaard |
|--------------------------+----------------------------------------|
| Reason for reporting | Chief Financial Officer |
|--------------------------+----------------------------------------|
| Financial instrument and | Novo Nordisk B shares DK 006010261 |
| ID code | |
|--------------------------+----------------------------------------|
| Type of transaction | Other transaction (transfer of shares |
| | in accordance with long-term incentive |
| | programme) |
|--------------------------+----------------------------------------|
| Date of transaction | 31 January 2008 |
|--------------------------+----------------------------------------|
| Place of transaction | OMX The Nordic Exchange Copenhagen |
|--------------------------+----------------------------------------|
| Volume of transaction | 17,426 shares |
|--------------------------+----------------------------------------|
| Total value of | DKK 0 (transferred in accordance with |
| transaction | the long-term incentive programme for |
| | 2004) |
+-------------------------------------------------------------------+
+-------------------------------------------------------------------+
| Name | Jesper Brandgaard |
|---------------------------------+---------------------------------|
| Reason for reporting | Chief Financial Officer |
|---------------------------------+---------------------------------|
| Financial instrument and ID | Novo Nordisk B shares DK |
| code | 006010261 |
|---------------------------------+---------------------------------|
| Type of transaction | Sale of shares |
|---------------------------------+---------------------------------|
| Date of transaction | 31 January 2008 |
|---------------------------------+---------------------------------|
| Place of transaction | OMX The Nordic Exchange |
| | Copenhagen |
|---------------------------------+---------------------------------|
| Volume of transaction | 17,426 shares |
|---------------------------------+---------------------------------|
| Total value of transaction | DKK 5,422,274 |
+-------------------------------------------------------------------+
+-------------------------------------------------------------------+
| Name | Lise Kingo |
|--------------------------+----------------------------------------|
| Reason for reporting | Chief of Staffs |
|--------------------------+----------------------------------------|
| Financial instrument and | Novo Nordisk B shares DK 006010261 |
| ID code | |
|--------------------------+----------------------------------------|
| Type of transaction | Other transaction (transfer of shares |
| | in accordance with long-term incentive |
| | programme) |
|--------------------------+----------------------------------------|
| Date of transaction | 31 January 2008 |
|--------------------------+----------------------------------------|
| Place of transaction | OMX The Nordic Exchange Copenhagen |
|--------------------------+----------------------------------------|
| Volume of transaction | 17,426 shares |
|--------------------------+----------------------------------------|
| Total value of | DKK 0 (transferred in accordance with |
| transaction | the long-term incentive programme for |
| | 2004) |
+-------------------------------------------------------------------+
+-------------------------------------------------------------------+
| Name | Lise Kingo |
|---------------------------------+---------------------------------|
| Reason for reporting | Chief of Staffs |
|---------------------------------+---------------------------------|
| Financial instrument and ID | Novo Nordisk B shares DK |
| code | 006010261 |
|---------------------------------+---------------------------------|
| Type of transaction | Sale of shares |
|---------------------------------+---------------------------------|
| Date of transaction | 31 January 2008 |
|---------------------------------+---------------------------------|
| Place of transaction | OMX The Nordic Exchange |
| | Copenhagen |
|---------------------------------+---------------------------------|
| Volume of transaction | 17,426 shares |
|---------------------------------+---------------------------------|
| Total value of transaction | DKK 5,422,274 |
+-------------------------------------------------------------------+
+-------------------------------------------------------------------+
| Name | Kåre Schultz |
|--------------------------+----------------------------------------|
| Reason for reporting | Chief Operating Officer |
|--------------------------+----------------------------------------|
| Financial instrument and | Novo Nordisk B shares DK 006010261 |
| ID code | |
|--------------------------+----------------------------------------|
| Type of transaction | Other transaction (transfer of shares |
| | in accordance with long-term incentive |
| | programme) |
|--------------------------+----------------------------------------|
| Date of transaction | 31 January 2008 |
|--------------------------+----------------------------------------|
| Place of transaction | OMX The Nordic Exchange Copenhagen |
|--------------------------+----------------------------------------|
| Volume of transaction | 17,426 shares |
|--------------------------+----------------------------------------|
| Total value of | DKK 0 (transferred in accordance with |
| transaction | the long-term incentive programme for |
| | 2004) |
+-------------------------------------------------------------------+
+-------------------------------------------------------------------+
| Name | Mads Krogsgaard Thomsen |
|--------------------------+----------------------------------------|
| Reason for reporting | Chief Science Officer |
|--------------------------+----------------------------------------|
| Financial instrument and | Novo Nordisk B shares DK 006010261 |
| ID code | |
|--------------------------+----------------------------------------|
| Type of transaction | Other transaction (transfer of shares |
| | in accordance with long-term incentive |
| | programme) |
|--------------------------+----------------------------------------|
| Date of transaction | 31 January 2008 |
|--------------------------+----------------------------------------|
| Place of transaction | OMX The Nordic Exchange Copenhagen |
|--------------------------+----------------------------------------|
| Volume of transaction | 17,426 shares |
|--------------------------+----------------------------------------|
| Total value of | DKK 0 (transferred in accordance with |
| transaction | the long-term incentive programme for |
| | 2004) |
+-------------------------------------------------------------------+
+-------------------------------------------------------------------+
| Name | Mads Krogsgaard Thomsen |
|---------------------------------+---------------------------------|
| Reason for reporting | Chief Science Officer |
|---------------------------------+---------------------------------|
| Financial instrument and ID | Novo Nordisk B shares DK |
| code | 006010261 |
|---------------------------------+---------------------------------|
| Type of transaction | Sale of shares |
|---------------------------------+---------------------------------|
| Date of transaction | 31 January 2008 |
|---------------------------------+---------------------------------|
| Place of transaction | OMX The Nordic Exchange |
| | Copenhagen |
|---------------------------------+---------------------------------|
| Volume of transaction | 17,426 shares |
|---------------------------------+---------------------------------|
| Total value of transaction | DKK 5,422,274 |
+-------------------------------------------------------------------+
Definitions and background information:
Publication
Publication shall take place the day after Novo Nordisk receives
sufficient information on the trading. Publication is only required
when the total amount of transactions of a specific board
member/executive and his/her associated persons in any one calendar
year has reached 5,000 euros.
Who are board members, executives and associated persons?
Board members and executives are members of the Board of Directors
and Executive Management, respectively, of Novo Nordisk A/S.
Associated persons are defined as the following persons associated to
a board member/executive: 1) spouse or cohabitant, 2) children under
the age of 18 years, 3) relatives defined as brothers, sisters,
parents, grandparents etc, children, grandchildren etc who have
shared the same household with a board member/executive for at least
one year, and 4) any legal person, including a company, a foundation
or a partnership, which is controlled directly or indirectly by a
board member/executive and/or a person mentioned in 1)-3), or to
which a board member/executive and/or a person mentioned in 1)-3) has
managerial responsibilities or economic interests substantially
equivalent to the legal person.
What is trading/transaction?
Trading is any kind of transaction, including shares purchased or
otherwise acquired, shares sold or otherwise disposed, gifts,
mortgages and grants and exercise of options, but not heritage.
What is financial instrument and ID code?
Financial instrument includes shares listed on the OMX The Nordic
Exchange Copenhagen and London Stock Exchange as well as ADRs listed
on New York Stock Exchange, except for ADRs held in 401(k) retirement
plan by US-based employees. The ID code is the code (ISIN
DK006010261) of the Novo Nordisk share on OMX The Nordic Exchange
Copenhagen, the code (NVOB) on London Stock Exchange or the code
(NVO) on New York Stock Exchange.
What is date and place of transaction?
Date of transaction is the actual transaction date. The place of
transaction is the actual place of transaction, ie OMX The Nordic
Exchange Copenhagen, London Stock Exchange or New York Stock
Exchange.
What is volume and value of transaction?
The volume of transaction is the number of shares (of DKK 1 nominal
value) or other financial instruments traded. The transaction value
is the number of shares traded multiplied by the transaction price.
The exchange rate of the Danish Central Bank (Nationalbanken) on the
date of transaction is used for calculating the transaction value in
DKK in case of shares traded on London Stock Exchange and ADRs listed
on New York Stock Exchange.
For further information please contact:
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,000
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
For further information please contact:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 4 / 2008